There's a handful of reasons that mature b-cell #lymphomas are treatment sensitive and often cured even when at an advanced stage.

One being, immune cells, lymphocytes, are inherently prone to dye off after its job is done, - and very sensitive to chemo and radiation.

Another: you can target and kill the mature forms of b-cells and more will be regenerated from stem cells. The immature cells don't yet have the cd20, or cd19, or cd22 molecule on the cell surface.

https://pubmed.ncbi.nlm.nih.gov/41100732/

Corriere.it - Homepage by di Vera Martinella
Nuove possibilità per la cura dei linfomi: così cambia in meglio la vita dei pazienti 

La rimborsabilità in Italia di farmaci innovativi mette a disposizione dei malati opzioni che migliorano sia le prospettive sia la qualità della vita. Crescono anche le probabilità di guarire

Translated:
New possibilities for the treatment of lymphomas: this is how life improves for patients.

In Italy, the reimbursement of innovative drugs provides patients with options that improve both their prospects and quality of life. The chances of recovery also increase.

#Italy #drug #lymphomas
https://www.corriere.it/salute/sportello_cancro/24_ottobre_01/nuove-possibilita-per-la-cura-dei-linfomi-8b74e635-dc1f-40c6-8cf1-089a84f24xlk.shtml

#Medmastodon

Mycosis Fungoides (MF) and Sezary syndrome(SS) are extra-nodal cutaneous T cell #lymphomas

Long term outcomes of non-myeloablative allogeneic stem cell rescue for MF and SS - full text:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11161400/

Cancers are typically clonal -- a tumor of many cells arising from a single cell of origin.

In immune-cell cancers this is easily ascertained because each cell will have a molecule with affinity to one antigen.

Just my thought: that Bi-clonal #lymphomas are rare supports the notion that bad luck - random copy errors - is the most common cause for #cancer; else poly-clonal cancers would be common. @dcnorris

#cancer #news

The abstract is unreadable for me but the flow chart describes the methods of the study well.

CAR T-cell therapy (axicabtagene ciloleucel treatment) is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell #lymphomas the Italian CART-SIE study

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11073993/

#Medmastodon #cancer

"Numerically higher" ... as in heads out numbering tails in 52 coin flips?

Effect of atorvastatin versus placebo on efficacy in patients with diffuse large B-cell #Lymphomas receiving R-CHOP

🔬💉 #Lymphomas: Cologne researchers have developed an innovative strategy to make CAR-T cell therapy for lymph node cancer safer and more effective.

💡 The idea: an "AND" switch ensures that tumour cells are attacked in a more targeted manner because they are only attacked if two specific proteins are present on the cell surface.

Read more ➡️ https://uni.koeln/NMEK4

The paper was published in Cell Reports Medicine 👇
https://www.sciencedirect.com/science/article/pii/S2666379124000442

#MEDMASTODON
"The right drug for the right patient" -- the promise of personalized medicine

... but I'm not sure that the study methods are sufficient to justify the conclusions. The reason I'm thankful for peer review.

CD5 Gene Signature Identifies Diffuse Large B-Cell #Lymphomas Sensitive to Bruton's Tyrosine Kinase (BTK) Inhibition

https://pubmed.ncbi.nlm.nih.gov/38079587/

#Cancer #fedscience
#ClinicalResearch #Oncology #Medicine #lymsm @[email protected]

Researchers discovered how T-cell #lymphomas grow so quickly and how this process can be stopped by inhibiting the tumor's sugar uptake, causing its cells to die off: http://go.tum.de/776233

#cancercells #genes #sugarmetabolism

📷A. Eckert

CD4+ CAR T-cell expansion is associated with response and therapy-related toxicities in patients with B-cell #lymphomas

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471494/

#MEDMASTODON #lymphoma #Cancer
#ClinicalResearch #Oncology #Medicine #lymsm @[email protected]